FDA coverage on Peptide News Digest follows the agency's actual paper trail: approval letters, warning letters, PCAC meeting minutes, 503A bulks list rulings, draft guidance, and Citizen Petitions on substances ranging from semaglutide to BPC-157.
The center of gravity in 2025 and 2026 has been compounding. Once GLP-1 shortages resolved, the agency turned to enforcement — 503A patient-specific compounding versus 503B outsourcing, which APIs sit on which list, what counts as a 'clinical need,' and whether additive formulations count as new drugs. The April 30, 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list is the most consequential single move so far.
Outside GLP-1, the FDA has been active on peptide-vendor warning letters, advisory committee votes (PCAC, Endocrinologic and Metabolic Drugs), and the long grind of Section 503A's bulks list. Browse the latest below.
Novo Nordisk said on Friday, October 2, 2026 that the FDA's review of its biologics license application for denecimig, a bispecific antibody that mimics activated clotting factor VIII in hemophilia A, is still ongoing with no new action date because of remediation work at a manufacturing facility. Novo filed in September 2025 and had expected a decision in the third quarter of 2026; the FDA has not identified deficiencies in the clinical efficacy or safety data, and Novo now aims to launch in the U.S. in the first half of 2027. The company said the delay does not change its 2026 financial outlook.
STAT reported on Monday, October 5, 2026 from PepMed 2026, a conference for regenerative health businesses held by the American Academy of Peptide Medicine, that stem cell entrepreneurs see the FDA's recent openness to compounded peptides as a model for bringing unapproved stem cell therapies out of the gray market. Entrepreneur Chuck Meeker predicted a series of FDA roundtables on stem cells before the end of the year; the FDA declined to say whether any were planned. Commercially sold, unapproved stem cell therapies have remained out of favor with the agency.
As of Tuesday September 8, 2026, the FDA has issued no proposed rule, no Federal Register notice, and no interim enforcement policy following the July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) 5-3 vote recommending six of seven candidate peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for inclusion on the Section 503A Bulk Drug Substances List; emideltide (DSIP) was rejected. Forty-six days have passed since the meeting ended on July 24. Center for Drug Evaluation and Research warning-letter activity to compounding pharmacies has remained elevated through Q3 2026, and no acting-FDA-commissioner statement has updated the industry timeline. The February 2027 PCAC meeting to consider cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and PEG-MGF remains scheduled. Nominated FDA Commissioner Dr. Heidi Overton (August 19, 2026) continues to await Senate confirmation with Kyle Diamantas leading the agency in the interim. Formal FDA rulemaking to translate the PCAC recommendation into a proposed rule and then a final rule typically runs 12 to 24 months from PCAC vote; the interval of 46 days is within the normal window but longer than industry advocates had modeled at the meeting.
As of Sunday September 6, 2026, the FDA has issued no proposed rule, no Federal Register notice, and no interim enforcement policy following the July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) vote to recommend six peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for inclusion on the Section 503A Bulk Drug Substances List. The regulatory silence has now lasted 44 days since the meeting ended on July 24, and compounding pharmacies continue to operate in the gray zone that began with the April 16, 2026 removal of 12 peptides from Category 2. Center for Drug Evaluation and Research warning-letter activity to compounding pharmacies remained elevated through Q3 2026. The February 2027 PCAC meeting to consider cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and pegylated mechano growth factor (PEG-MGF) remains scheduled. Dr. Heidi Overton (nominated FDA Commissioner August 19, 2026) continues to await Senate confirmation. Formal FDA rulemaking to translate the July PCAC recommendation into a proposed rule and then a final rule typically runs 12 to 24 months from PCAC vote; the interval of just over six weeks is within the normal window but longer than industry advocates had modeled.
As of Saturday September 5, 2026, the FDA has issued no proposed rule, no Federal Register notice, and no interim enforcement policy following the July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) vote to recommend six peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for inclusion on the Section 503A Bulk Drug Substances List. The regulatory silence has now extended six weeks past the vote and continues to leave compounding pharmacies operating in the gray zone that began with the April 16, 2026 removal of 12 peptides from Category 2. Center for Drug Evaluation and Research warning-letter activity to compounding pharmacies has remained elevated through Q3 2026. The February 2027 PCAC meeting to consider cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and pegylated mechano growth factor (PEG-MGF) remains scheduled. Dr. Heidi Overton (nominated FDA Commissioner August 19, 2026) continues to await Senate confirmation with acting Commissioner Kyle Diamantas leading the agency through the interim.
The U.S. Food and Drug Administration confirmed via press announcement Friday September 4, 2026 that it will convene a joint workshop with the European Medicines Agency (EMA) on Friday September 25, 2026 to discuss regulatory considerations for herbal medicinal and botanical drug products intended for medicinal use. The workshop follows the FDA's ongoing public-input process on botanical drug development that generated substantial biotech and pharmaceutical industry commentary earlier in 2026. Botanical drugs occupy an underdeveloped regulatory category in the U.S. — FDA has approved only two botanical drugs to date (Veregen sinecatechins from green tea for genital warts, approved 2006; Fulyzaq crofelemer from Croton lechleri sap for HIV-related diarrhea, approved 2012). Proposed legislation in the U.S. would extend 12-year market exclusivity to FDA-approved botanical drugs, matching the biologics exclusivity framework. The Sept 25 workshop matters for the peptide-industry pipeline because plant-derived and marine-organism-derived peptide products (defensins, ranatuerin analogs, plant-defensin-based antimicrobials) occupy a similar regulatory gray zone between conventional pharmaceuticals and dietary supplements.
As of Thursday September 3, 2026, the FDA has issued no proposed rule, no Federal Register notice, and no interim enforcement policy following the July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) vote to recommend six peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for inclusion on the Section 503A Bulk Drug Substances List. The regulatory silence extends the gray zone that began with the April 16, 2026 removal of 12 peptides from Category 2 and continues to leave compounding pharmacies operating under enforcement risk. CDER warning-letter activity to compounding pharmacies remained elevated through Q3 2026 versus prior years. The February 2027 PCAC meeting to consider cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and pegylated mechano growth factor (PEG-MGF) remains scheduled; formal FDA rulemaking to translate PCAC recommendations into a proposed rule typically runs 6 to 18 months. The FDA Commissioner nomination of Dr. Heidi Overton continues to await Senate confirmation, with acting Commissioner Kyle Diamantas leading the agency through the interim.
Holland & Knight and Mondaq legal analyses published following the July 23-24, 2026 FDA Pharmacy Compounding Advisory Committee (PCAC) vote clarify the rulemaking process for the six recommended peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon; Emideltide/DSIP rejected). Key legal clarifications: PCAC recommendations are advisory only; HHS Secretary Robert F. Kennedy Jr. must formally approve the substances for Section 503A Bulks List inclusion; no compounding pharmacy is permitted to legally compound the peptides until final rulemaking completes; formal rulemaking typically takes 12-24 months from advisory-committee recommendation (Notice of Proposed Rulemaking, public comment period, response to comments, final rule with effective date). Even after final rule takes effect, individual states retain authority under state pharmacy board oversight to further restrict or condition compounded-peptide preparation. Separately, the FDA has announced a second PCAC peptide meeting before the end of February 2027 to review five additional peptides: cathelicidin (LL-37, antimicrobial peptide), GHK-Cu (copper tripeptide cosmetic peptide), dihexa acetate (nootropic), melanotan II (α-MSH analog), and pegylated mechano growth factor (PEG-MGF, muscle repair). Combined, the July 2026 and February 2027 PCAC dockets bring 12 peptides through advisory-committee review as part of the broader Trump administration and HHS Secretary RFK Jr. peptide deregulation agenda that has moved through the regulatory system since Q1 2026.
The FDA Pharmacy Compounding Advisory Committee (PCAC) has scheduled a second peptide meeting before the end of February 2027 to review five additional peptides for Section 503A Bulks List inclusion. The February 2027 docket covers: cathelicidin (LL-37), a broad-spectrum antimicrobial peptide with anti-infective and immune-modulatory activity; GHK-Cu (glycyl-histidyl-lysine copper tripeptide), a widely-marketed cosmetic and wound-healing peptide previously in FDA Category 2; dihexa acetate, an angiotensin IV-derived nootropic that has been marketed for cognitive enhancement; melanotan II, an alpha-melanocyte-stimulating hormone analog marketed for skin pigmentation (self-tanning) and appetite suppression; and pegylated mechano growth factor (PEG-MGF), a muscle-repair peptide derived from insulin-like growth factor 1 splice variants. The February 2027 review continues the July 23-24, 2026 PCAC session that recommended 6 of 7 peptides for Section 503A Bulks List inclusion (BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon approved; Emideltide/DSIP rejected). FDA has not yet posted the final date and public-comment docket details for the February 2027 meeting. Under standard rulemaking timelines, the FDA's process of Notice of Proposed Rulemaking, public comment period, and final rule after any positive PCAC recommendation takes 12-24 months.
The FDA public comment period on the April 30, 2026 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the Section 503B Bulks List closed Thursday July 30, 2026 after a Federal Register-extended deadline from the original June 29 cutoff. The FDA's underlying finding: no clinical need for FDA-registered outsourcing facilities to compound the three GLP-1 molecules from bulk drug substances. Section 503B outsourcing facilities are the FDA-registered large-scale compounding manufacturers (as distinct from state-licensed 503A pharmacies that compound for individual patient prescriptions). Finalization of the proposed rule would close the last legal pathway for large-scale FDA-registered 503B outsourcing facility compounding of the branded GLP-1 molecules, following the December 2024 semaglutide shortage resolution and February 2025 tirzepatide shortage resolution that ended the shortage-based compounding pathway. FDA rulemaking to finalize the exclusion after comment-period close typically takes 3-9 months depending on the volume and substance of received comments. Telehealth platforms including Hims & Hers Health (NYSE: HIMS) and LifeMD have already migrated to branded supply through Novo Nordisk and Eli Lilly commercial channels ahead of the expected 503B closure. FDA Adverse Event Reporting System (FAERS) data as of the July 2026 safety statement: 990 adverse events linked to compounded semaglutide, over 730 for compounded tirzepatide.
The FDA public comment period on the April 30, 2026 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the Section 503B Bulks List closed Thursday July 30, 2026. If the FDA finalizes the rule, large-scale FDA-registered 503B outsourcing facilities will no longer be able to legally prepare compounded semaglutide, tirzepatide, or liraglutide once the shortage-based compounding pathway has fully closed. The 503B exclusion is the parallel-track regulatory action to the July 23-24 PCAC vote on the 7 research peptides for the 503A Bulks List. Where 503A operates under state pharmacy board licensure for individual-patient prescriptions, 503B operates under FDA registration for bulk manufacturing at outsourcing facilities. The 503A vote broadened access to 6 of 7 research peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon; DSIP rejected). The 503B exclusion narrows access for the branded GLP-1 franchise. Both actions require FDA rulemaking to formalize, with typical timelines of 6-18 months from the date the agency decides to act. Telehealth companies including Hims & Hers Health (NYSE: HIMS) and LifeMD (NASDAQ: LFMD) have already migrated to branded supply through Novo Nordisk and Eli Lilly commercial channels ahead of the expected 503B closure.
The FDA Pharmacy Compounding Advisory Committee (PCAC) closed the two-day peptide session Friday July 24, 2026 with two more advisory wins and one narrow rejection. Semax, a synthetic heptapeptide derived from the ACTH(4-10) sequence developed in Russia as a nootropic, was recommended 8-5 for the Section 503A Bulks List for adult cerebral ischemia, migraine, and trigeminal neuralgia. Epitalon, a synthetic tetrapeptide nominated for insomnia and anti-aging, was recommended 7-4 for adult insomnia. Emideltide (delta sleep-inducing peptide, DSIP), a nonapeptide first isolated from rabbit brain in 1974 and nominated for insomnia and opioid withdrawal, was narrowly voted against, the sole rejection of the two-day session. STAT News framed the Day 2 outcome as 'FDA advisory panel narrowly rejects compounding of one peptide, backs two others.' FDA career-staff briefing documents released June 29-30 recommended against all three Day-2 peptides, citing insufficient evidence of effectiveness for Epitalon in insomnia and 'balancing of the criteria weighs against' Semax. The recommendations are advisory only.
Day 1 afternoon session vote tallies clarified Friday for Thursday July 23, 2026: the FDA Pharmacy Compounding Advisory Committee (PCAC) voted 8-6 to recommend adding TB-500 (thymosin beta-4 fragment, marketed for wound healing and tissue repair) to the Section 503A Bulks List, and voted 7-5 with 2 abstentions to recommend adding MOTS-c (mitochondrial-derived peptide, nominated for obesity and metabolic disease). Both afternoon votes followed the morning session votes on BPC-157 (8-6, 1 abstention) and KPV (8-6, 1 abstention), making Thursday a clean sweep of all four Day-1 peptides. Every Day-1 win overrode the FDA career-staff briefing documents released June 29-30, which recommended against adding any of the seven peptides under review. Coverage across US News, ABC News, Bloomberg, The Hill, and Medical Daily converged on the framing that FDA career scientists were rebuked by the advisory panel on Day 1. TB-500 has been actively marketed alongside BPC-157 in 'tissue repair' and 'recovery' peptide-clinic protocols; MOTS-c has been marketed for metabolic health and mitochondrial function despite thin human clinical evidence.
The two-day FDA Pharmacy Compounding Advisory Committee (PCAC) session closed Friday July 24, 2026 with 6 of 7 research peptides recommended for the Section 503A Bulks List. Day 1 wins: BPC-157 (8-6-1), KPV (8-6-1), TB-500 (8-6), MOTS-c (7-5-2). Day 2 wins: Semax (8-5), Epitalon (7-4). Day 2 rejection: Emideltide/DSIP. Every one of the 6 wins overrode the FDA career-staff briefing documents that recommended against adding any of the seven peptides. STAT News, Time Magazine, NPR, ABC News, Bloomberg, US News, The Hill, and Washington Times converged on the framing that HHS Secretary Robert F. Kennedy Jr.'s peptide-access push cleared a substantive advisory threshold. Panel composition itself was a substantive factor: eight new PCAC members were named June 29, with at least seven documented to have peptide-industry ties per STAT News. What still has to happen before actual compounding-pharmacy access changes: FDA leadership must review each vote, decide whether to accept it, publish a proposed rule in the Federal Register, run a 60-90 day public comment period, respond to comments, and publish a final rule with an effective date. Rulemaking typically takes 6-18 months per substance from the date the FDA decides to act.
The FDA Pharmacy Compounding Advisory Committee (PCAC) voted 8-6 with 1 abstention on Thursday July 23, 2026 to recommend adding BPC-157 to the Section 503A Bulk Drug Substances List, in a win for HHS Secretary Robert F. Kennedy Jr.'s peptide deregulation agenda. The narrow vote overrode FDA career-staff briefing documents released June 29-30 that recommended against adding any of the seven peptides under review, citing immunogenicity concerns, heavy-metal and microbial contamination in samples pulled from the compounding channel, mislabeled contents, and thin 503A historical use. The vote sequencing during the Thursday session followed extensive public comment; Hims Chief Medical Officer Dr. Anant Vinjamoori argued during his testimony that a no vote would push peptides deeper into an unregulated gray market rather than end the underlying demand. PCAC recommendations are advisory and non-binding; the FDA typically follows them, and formal rulemaking to implement the recommendation would take approximately 6 to 18 months. Panel composition is a significant contextual factor: before the meeting, more than a half-dozen new members with documented ties to the peptide industry were added to the PCAC.
The FDA Pharmacy Compounding Advisory Committee (PCAC) voted identically 8-6 with 1 abstention on Thursday July 23, 2026 to recommend adding KPV to the Section 503A Bulk Drug Substances List. KPV is a tripeptide (lysine-proline-valine) derived from alpha-melanocyte-stimulating hormone (α-MSH) with anti-inflammatory activity documented primarily in preclinical inflammatory bowel disease and colitis models. It was nominated for ulcerative colitis and inflammatory conditions. FDA career staff recommended against adding KPV, noting thin human clinical trial evidence and 503A historical use questions. The 8-6 KPV vote matches the identical BPC-157 vote earlier in the session and reflects a coordinated panel disposition to override the FDA staff position on the two Day-1 morning peptides. The PCAC session continues Thursday afternoon with votes on TB-500 (thymosin beta-4 fragment for wound healing and tissue repair) and MOTS-c (mitochondrial-derived peptide for obesity and metabolic disease). The Friday July 24 session covers DSIP/Emideltide (delta sleep-inducing peptide), Semax (heptapeptide ACTH analog for cerebral ischemia and cognition), and Epitalon (tetrapeptide for anti-aging and insomnia).
The FDA Pharmacy Compounding Advisory Committee (PCAC) reconvenes Friday July 24, 2026 at 8:00 AM ET at FDA's White Oak Campus in Silver Spring, Maryland for Day 2 of the peptide review. Friday's schedule covers three peptides: DSIP/Emideltide (delta sleep-inducing peptide, a nonapeptide first isolated from rabbit brain in 1974 and nominated for sleep disorders and opioid withdrawal); Semax (a synthetic heptapeptide derived from the ACTH(4-10) sequence developed in Russia as a nootropic and nominated for cerebral ischemia, migraine, and trigeminal neuralgia); and Epitalon (a synthetic tetrapeptide nominated for insomnia and anti-aging applications). FDA career-staff briefing documents recommend against adding any of the three peptides to the Section 503A Bulks List. Panel composition (with at least seven of eight new members carrying peptide-industry ties per STAT News reporting) and Thursday's 8-6 BPC-157 and KPV votes suggest similar narrow majorities may recommend the Day-2 substances against career-staff positions. The Friday session closes at 3:50 PM ET. FDA rulemaking to implement any advisory recommendation would take approximately 6-18 months.
The FDA Pharmacy Compounding Advisory Committee (PCAC) written-comment docket FDA-2025-N-6895 closes at 11:59 PM ET on Wednesday July 22, 2026. Approximately 1,860 public comments have been filed on the seven-peptide review, spanning docket comments from institutional commenters supporting inclusion (Hims & Hers Health among them) and opposing inclusion (PhRMA, Partnership for Safe Medicines, American Pharmacists Association, Public Citizen, Institute for Safe Medication Practices, UC Davis's Paul Knoepfler). Hims Chief Medical Officer Dr. Anant Vinjamoori confirmed Hims will testify at Thursday's July 23 hearing at FDA's White Oak Campus in Silver Spring, Maryland. In pre-hearing remarks, Dr. Vinjamoori said medical providers should be honest about 'the relatively sparse clinical evidence for these peptides' but noted that Hims plans to offer the peptides if the FDA reclassifies them. He also cited nearly a decade of accumulated experience across 'thousands of physicians, close to millions of patients' that in his view supports the peptides' health benefits. FDA career-staff briefing documents recommend against adding any of the seven peptides to the 503A Bulks List. PCAC recommendations are advisory; FDA rulemaking (typically 6-18 months) is required before compounding pharmacies can act on any positive committee recommendation.